Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 183


Effects of metformin and alogliptin on body composition in people with type 2 diabetes.

Takeshita Y, Kita Y, Kato KI, Kanamori T, Misu H, Kaneko S, Takamura T.

J Diabetes Investig. 2018 Aug 29. doi: 10.1111/jdi.12920. [Epub ahead of print]


Pd/PTABS: An Efficient Water-Soluble Catalytic System for the Amination of 6-Chloropurine Ribonucleoside and Synthesis of Alogliptin.

Bhilare S, Bandaru SSM, Kapdi AR, Sanghvi YS, Schulzke C.

Curr Protoc Nucleic Acid Chem. 2018 Sep;74(1):e58. doi: 10.1002/cpnc.58. Epub 2018 Aug 21.



Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.


Smart spectrophotometric methods based on normalized spectra for simultaneous determination of alogliptin and metformin in their combined tablets.

Lamie NT, Mahrouse MA.

Spectrochim Acta A Mol Biomol Spectrosc. 2018 Nov 5;204:743-747. doi: 10.1016/j.saa.2018.07.004. Epub 2018 Jul 4.


A high-performance liquid chromatography-tandem mass spectrometry method for simultaneous determination of imigliptin, its five metabolites and alogliptin in human plasma and urine and its application to a multiple-dose pharmacokinetic study.

Liu Y, Song L, Yao X, Wu Y, Liu H, Zhao Q, Jiang J, Shi C, Ma X, Zhou H, Liu D, Hu P.

Biomed Chromatogr. 2018 Jun 27:e4324. doi: 10.1002/bmc.4324. [Epub ahead of print]



Terrell JM, Jacobs TF.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2018 Jun 11.


Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.

White WB, Heller SR, Cannon CP, Howitt H, Khunti K, Bergenstal RM; EXAMINE Investigators.

Am J Med. 2018 Jul;131(7):813-819.e5. doi: 10.1016/j.amjmed.2018.02.023. Epub 2018 Mar 23.


Alogliptin and Gliclazide Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients.

Negro R, Greco EL, Greco G.

Exp Clin Endocrinol Diabetes. 2018 Mar 20. doi: 10.1055/s-0043-122383. [Epub ahead of print]


Alogliptin alleviates hepatic steatosis in a mouse model of nonalcoholic fatty liver disease by promoting CPT1a expression via Thr172 phosphorylation of AMPKα in the liver.

Tobita H, Sato S, Yazaki T, Mishiro T, Ishimura N, Ishihara S, Kinoshita Y.

Mol Med Rep. 2018 May;17(5):6840-6846. doi: 10.3892/mmr.2018.8673. Epub 2018 Mar 1.


Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis.

Amano Y, Tsuchiya S, Imai M, Tohyama K, Matsukawa J, Isono O, Yasuno H, Enya K, Koumura E, Nagabukuro H.

Biochem Biophys Res Commun. 2018 Feb 26;497(1):207-213. doi: 10.1016/j.bbrc.2018.02.055. Epub 2018 Feb 9.


Evaluation of the Effect of Alogliptin on Tissue Characteristics of the Carotid Wall: Subanalysis of the SPEAD-A Trial.

Irie Y, Katakami N, Mita T, Takahara M, Matsuoka TA, Gosho M, Watada H, Shimomura I; Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Collaborators.

Diabetes Ther. 2018 Feb;9(1):317-329. doi: 10.1007/s13300-018-0367-7. Epub 2018 Jan 12.


Ethnic Differences in Efficacy and Safety of Alogliptin: A Systematic Review and Meta-Analysis.

Cai Y, Zeng T, Wen Z, Chen L.

Diabetes Ther. 2018 Feb;9(1):177-191. doi: 10.1007/s13300-017-0352-6. Epub 2017 Dec 20.


Active Stromal Cell-Derived Factor 1α and Endothelial Progenitor Cells are Equally Increased by Alogliptin in Good and Poor Diabetes Control.

Negro R, Greco EL, Greco G.

Clin Med Insights Endocrinol Diabetes. 2017 Nov 27;10:1179551417743980. doi: 10.1177/1179551417743980. eCollection 2017.


Efficacy of alogliptin combined with motor imagery under hyperbaric oxygen in diabetic nephropathy with silent cerebral infarction.

Chen D, Huang X, Gan H, Du X, Lu S, Huang R, Liu K, Zhang B.

Biomed Rep. 2017 Nov;7(5):407-415. doi: 10.3892/br.2017.983. Epub 2017 Sep 14.


Zinc/alogliptin combination attenuates testicular toxicity induced by doxorubicin in rats: Role of oxidative stress, apoptosis and TGF-β1/NF-κB signaling.

Kabel AM.

Biomed Pharmacother. 2018 Jan;97:439-449. doi: 10.1016/j.biopha.2017.10.144. Epub 2017 Nov 6.


High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.

Hwang YC, Morrow DA, Cannon CP, Liu Y, Bergenstal R, Heller S, Mehta C, Cushman W, Bakris GL, Zannad F, White WB.

Diabetes Obes Metab. 2018 Mar;20(3):654-659. doi: 10.1111/dom.13136. Epub 2017 Nov 21.


Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients.

Kurozumi A, Okada Y, Arao T, Kobayashi T, Masuda D, Yamashita S, Tanaka Y.

J Diabetes Investig. 2018 Mar;9(2):360-365. doi: 10.1111/jdi.12739. Epub 2017 Oct 3.


Antidiabetic Drug Alogliptin Protects the Heart Against Ischemia-reperfusion Injury Through GLP-1 Receptor-dependent and Receptor-independent Pathways Involving Nitric Oxide Production in Rabbits.

Baba S, Iwasa M, Higashi K, Minatoguchi S, Yamada Y, Kanamori H, Kawasaki M, Nishigaki K, Minatoguchi S.

J Cardiovasc Pharmacol. 2017 Dec;70(6):382-389. doi: 10.1097/FJC.0000000000000531.


Long-Term Effect of Alogliptin on Glycemic Control in Japanese Patients With Type 2 Diabetes: A 3.5-Year Observational Study.

Takebayashi K, Suzuki T, Naruse R, Hara K, Suetsugu M, Tsuchiya T, Inukai T.

J Clin Med Res. 2017 Sep;9(9):802-808. doi: 10.14740/jocmr3118w. Epub 2017 Jul 27.

Supplemental Content

Loading ...
Support Center